| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:β-catenin-IN-3
CAS:1005288-15-2
Package:50mg;25mg;100mg
|
Thiourea, N-[2-(3,5-dibromo-2-hydroxyphenyl)ethenyl]-N'-(3a,4,5,6,7,7a-hexahydro-4,7-methano-1H-inden-5-yl)- manufacturers
- β-catenin-IN-3
-
- $0.00 / 50mg
-
2025-04-27
- CAS:1005288-15-2
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Thiourea, N-[2-(3,5-dibromo-2-hydroxyphenyl)ethenyl]-N'-(3a,4,5,6,7,7a-hexahydro-4,7-methano-1H-inden-5-yl)- Basic information |
| Product Name: | Thiourea, N-[2-(3,5-dibromo-2-hydroxyphenyl)ethenyl]-N'-(3a,4,5,6,7,7a-hexahydro-4,7-methano-1H-inden-5-yl)- | | Synonyms: | Thiourea, N-[2-(3,5-dibromo-2-hydroxyphenyl)ethenyl]-N'-(3a,4,5,6,7,7a-hexahydro-4,7-methano-1H-inden-5-yl)-;β-catenin-IN-3;β-catenin inhibitor C2 | | CAS: | 1005288-15-2 | | MF: | C19H20Br2N2OS | | MW: | 484.25 | | EINECS: | | | Product Categories: | | | Mol File: | 1005288-15-2.mol | ![Thiourea, N-[2-(3,5-dibromo-2-hydroxyphenyl)ethenyl]-N'-(3a,4,5,6,7,7a-hexahydro-4,7-methano-1H-inden-5-yl)- Structure](CAS/20210305/GIF/1005288-15-2.gif) |
| | Thiourea, N-[2-(3,5-dibromo-2-hydroxyphenyl)ethenyl]-N'-(3a,4,5,6,7,7a-hexahydro-4,7-methano-1H-inden-5-yl)- Chemical Properties |
| Boiling point | 539.4±60.0 °C(Predicted) | | density | 1.73±0.1 g/cm3(Predicted) | | pka | 7.56±0.50(Predicted) | | form | Solid | | color | White to off-white |
| | Thiourea, N-[2-(3,5-dibromo-2-hydroxyphenyl)ethenyl]-N'-(3a,4,5,6,7,7a-hexahydro-4,7-methano-1H-inden-5-yl)- Usage And Synthesis |
| Uses | β-catenin-IN-3 (Compound C2) is a selective β-catenin inhibitor. β-catenin-IN-3 binds to allosteric site on the surface of β-catenin with K D calculated at 54.96 nM. β-catenin-IN-3 selectively inhibits β-catenin via targeting a cryptic allosteric modulation site, lowers its cellular load. β-catenin-IN-3 significantly reduces viability of β-catenin driven cancer cells, and triggers β-catenin degradation via proteasome system in β-catenin-overexpressing cancer cells[1]. | | in vivo | β-catenin-IN-3 (25 mg/kg, i.p., 35 days) notably reduces β-catenin-dependent tumor growth represented in DLD1 xenograft model[1].
| Animal Model: | 6-week-old female NSG (NOD-SCID) mice were injected with 3 *106 DLD1 cells[1]. | | Dosage: | 25 mg/kg | | Administration: | i.p., 35 days | | Result: | Mice Did not display any signs of acute toxicity and body weight loss.
Inhibition of tumor growth by β-catenin-IN-3 was noted after 20 days of treatment, after which the tumor volume of β-catenin-IN-3 treated mice did not increase exponentially.
At day 35, the calculated tumor growth inhibition by β-catenin-IN-3 was 50% as compared to the vehicle.
|
| | IC 50 | Cdk4/cyclin D1 | | References | [1] Cheltsov A, et al. Allosteric inhibitor of β-catenin selectively targets oncogenic Wnt signaling in colon cancer. Sci Rep. 2020;10(1):8096. Published 2020 May 15. DOI:10.1038/s41598-020-60784-y |
| | Thiourea, N-[2-(3,5-dibromo-2-hydroxyphenyl)ethenyl]-N'-(3a,4,5,6,7,7a-hexahydro-4,7-methano-1H-inden-5-yl)- Preparation Products And Raw materials |
|